REFERENCES
1. Goodman CW, Brett AS. Gabapentin and pregabalin for pain — is increased prescribing a cause for concern? NEJM . 2017;377(5):411-4.
2. Evoy KE, Peckham AM, Covvey JR, Tidgewell KJ. Gabapentinoid pharmacology in the context of emerging misuse liability. J Clin Pharmacol . 2021;61(S2):S89-S99.
3. Schaffer AL, Busingye D, Chidwick K, Brett J, Blogg S. Pregabalin prescribing patterns in Australian general practice, 2012-2018: a cross-sectional study. BJGP Open. 2021;5(1):bjgpopen20X101120.
4. Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med . 2019;179(5):695-701.
5. Mathieson S, Valenti L, Maher CG, Britt H, Li Q, McLachlan AJ, et al. Worsening trends in analgesics recommended for spinal pain in primary care. Eur Spine J . 2018;27(5):1136-45.
6. Mathieson S, Lin CC, Underwood M, Eldabe S. Pregabalin and gabapentin for pain. BMJ . 2020;369:m1315.
7. Enke O, New HA, New CH, Mathieson S, McLachlan AJ, Latimer J, et al. Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. CMAJ . 2018;190(26):E786-E93.
8. Mathieson S, Maher CG, McLachlan AJ, Latimer J, Koes BW, Hancock MJ, et al. Trial of pregabalin for acute and chronic sciatica. NEJM . 2017;376(12):1111-1120.
9. Zhou L, Bhattacharjee S, Kwoh CK, Tighe PJ, Malone DC, Slack M, et al. Trends, patient and prescriber characteristics in gabapentinoid use in a sample of United States ambulatory care visits from 2003 to 2016.J Clin Med . 2019;9(1):83.
10. Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P. signal for an abuse liability for pregabalin—results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol . 2010;66(9):947-53.
11. Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol . 2013;69(6):1335-42.
12. Cairns R, Schaffer AL, Ryan N, Pearson SA, Buckley NA. Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings. Addiction . 2019;114(6):1026-34.
13. Kriikku P, Ojanperä I. Pregabalin and gabapentin in non-opioid poisoning deaths. Forensic Sci Int . 2021;324:110830.
14. Oh GY, Moga DC, Abner EL. Gabapentin utilization among older adults with different cognitive statuses enrolled in the National Alzheimer’s Coordinating Center (2006-2019). Br J Clin Pharmacol. 2022 Sep 13. doi: 10.1111/bcp.15532. Epub ahead of print.
15. Peltokorpi J, Hakko H, Riipinen P, Riala K. Profile of substance misuse among adolescent and young adult gabapentinoid users: a register-based follow-up study of former adolescent psychiatric inpatients. Subst Use Misuse. 2021;56(5):598-605.
16. Molero Y, Larsson H, D’Onofrio BM, Sharp DJ, Fazel S. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ . 2019;365:l2147.
17. McAnally H, Bonnet U, Kaye AD. Gabapentinoid benefit and risk stratification: mechanisms over myth. Pain Ther . 2020;9(2):441-52.
18. Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs . 2017;77(4):403-26.
19. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing.JAMA Intern Med . 2015;175(5):827-34.
20. Jansen J, Naganathan V, Carter SM, McLachlan A, Nickel B, Irwig L, et al. Too Much Medicine in older people? Deprescribing through Shared Decision Making. BMJ. 2016;353:i2893
21. Ailabouni N, Mangin D, Nishtala PS. DEFEAT-polypharmacy: deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities. Int J Clin Pharm . 2019;41(1):167-78.
22. Gannon JM, Lupu A, Brar J, Brandt M, Zawacki S, John S, et al. Deprescribing anticholinergic medication in the community mental health setting: a quality improvement initiative. Res Social Adm Pharm . 2021;17(10):1841-6.
23. Sawan MJ, Moga DC, Ma MJ, Ng JC, Johnell K, Gnjidic D. The value of deprescribing in older adults with dementia: a narrative review.Expert Rev Clin Pharmacol 2021;14(11):1367-82.
24. Mathieson S, Maher CG, Ferreira GE, Hamilton M, Jansen J, McLachlan AJ, et al. Deprescribing opioids in chronic non-cancer pain: systematic review of randomised trials. Drugs . 2020;80(15):1563-76.
25. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med . 2018;169(7):467-73.
26. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ . 2021;372:n71.
27. Collinson MJ. Reducing medication-related harm from gabapentinoids in primary care: A quality improvement project with a completed pdsa cycle. Age Ageing 2019;48(Supplement 2): ii1–ii10.
28. Chazot P, Johnson L, Hampshire K, Kinchin B, Cole F. Gabapentinoids and Opioids Tapering Tool box (GOTT): Midtrial evaluation. BJCP . 2021;87(12):4884-5.
29. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ . 2011;12(oct18 2):22-d5928.
30. Sterne JAC, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ . 2016;355:i4919-i.
31. McDonald EG, Wu PE, Rashidi B, Wilson MG, Bortolussi-Courval E, Atique A, et al. The MedSafer study-electronic decision support for deprescribing in hospitalized older adults: a cluster randomized clinical trial. JAMA Intern Med . 2022;182(3):265-73.
32. Kasper S, Iglesias-Garcia C, Schweizer E, Wilson J, DuBrava S, Prieto R, et al. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. Int J Neuropsychopharmacol . 2014;17(5):685-95.
33. National Institute for Health and Care Excellence. 2019 exceptional surveillance of neuropathic pain in adults: pharmacological management in non-specialist settings [CG173]. 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563975/.
34. Doherty AJ, Boland P, Reed J, Clegg AJ, Stephani A-M, Williams NH, et al. Barriers and facilitators to deprescribing in primary care: a systematic review. BJGP Open . 2020;4(3):bjgpopen20X101096.
35. Wiffen PJ, Derry S, Bell RF, Rice AS, Tolle TR, Phillips T, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev . 2017;6:CD007938.
36. Derry S, Cording M, Wiffen PJ, Law S, Phillips T, Moore RA. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev . 2016;9:CD011790.
37. Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev . 2019;1:CD007076.
38. Schjerning O, Rosenzweig M, Pottegård A, Damkier P, Nielsen J. Abuse potential of pregabalin: a systematic review. CNS Drugs . 2016;30(1):9-25.
39. Bastiaens L, Galus J, Mazur C. Abuse of gabapentin is associated with opioid addiction. Psychiatr Q . 2016;87(4):763-7.
40. Reeve E, Ong M, Wu A, Jansen J, Petrovic M, Gnjidic D. A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people. Eur J Clin Pharmacol . 2017;73(8):927-35.
41. Niznik JD, Collins BJ, Armistead LT, Larson CK, Kelley CJ, Hughes TD, et al. Pharmacist interventions to deprescribe opioids and benzodiazepines in older adults: a rapid review. Res Social Adm Pharm . 2022;18(6):2913-21.
42. Chen C, Winterstein AG, Lo-Ciganic W-H, Tighe PJ, Wei Y-JJ. Concurrent use of prescription gabapentinoids with opioids and risk for fall-related injury among older US Medicare beneficiaries with chronic noncancer pain: A population-based cohort study. PLoS Medicine. 2022;19:e1003921.
43. National Institute for Health and Care Excellence. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults [NG215]. 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK580680/.
44. Ng BJ, Le Couteur DG, Hilmer SN. Deprescribing Benzodiazepines in older patients: impact of interventions targeting physicians, pharmacists, and patients. Drugs Aging. 2018;35(6):493-521.
45. Garland EL, Manusov EG, Froeliger B, Kelly A, Williams JM, Howard MO. Mindfulness-Oriented Recovery Enhancement for Chronic pain and prescription opioid misuse: results from an early-stage randomized controlled trial. J Consult Clin Psychol . 2014;82(3):448-59.
46. Zheng Z, Gibson S, Helme RD, Wang Y, Lu DS-C, Arnold C, et al. Effects of Electroacupuncture on opioid consumption in patients with chronic musculoskeletal pain: a multicenter randomized controlled trial.Pain Medicine . 2019;20(2):397-410.